In order to achieve this, we gauged the expression of CTLA-4 and CD86 on immune cells in patients with CLL, and we linked the expression of these protein indicators of EBV infection and clinical outcomes. This evidence concerns the gene CTLA4 and Epstein-Barr virus infection.